Eli Lilly and Company (LLY) - Total Liabilities
Based on the latest financial reports, Eli Lilly and Company (LLY) has total liabilities worth $108.40 Billion USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore LLY long-term investments to assets to see how much of total assets are deployed in long-term investments.
Eli Lilly and Company - Total Liabilities Trend (1985–2025)
This chart illustrates how Eli Lilly and Company's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of Eli Lilly and Company.
Eli Lilly and Company Competitors by Total Liabilities
The table below lists competitors of Eli Lilly and Company ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tesla Inc
NASDAQ:TSLA
|
USA | $61.06 Billion |
|
SK Hynix Inc. American Depositary Shares
NASDAQ:SKHY
|
USA | $86.17 Trillion |
|
Space Exploration Technologies Corp. Class A Common Stock
NASDAQ:SPCX
|
USA | $65.55 Billion |
|
Walmart Inc
SA:WALM34
|
Brazil | R$192.56 Billion |
|
Samsung Electronics Co Ltd
KO:005930
|
Korea | ₩110.16 Trillion |
|
JPMorgan Chase & Co
NYSE:JPM
|
USA | $4.64 Trillion |
|
Walmart Inc. Common Stock
NYSE:WMT
|
USA | $192.56 Billion |
|
Eli Lilly and Company
SA:LILY34
|
Brazil | R$85.38 Billion |
Liability Composition Analysis (1985–2025)
This chart breaks down Eli Lilly and Company's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Eli Lilly and Company (LLY) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.35 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.76 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Eli Lilly and Company's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Eli Lilly and Company (1985–2025)
The table below shows the annual total liabilities of Eli Lilly and Company from 1985 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $85.94 Billion | +33.36% |
| 2024-12-31 | $64.44 Billion | +21.26% |
| 2023-12-31 | $53.14 Billion | +37.27% |
| 2022-12-31 | $38.71 Billion | -2.36% |
| 2021-12-31 | $39.65 Billion | -2.83% |
| 2020-12-31 | $40.81 Billion | +11.54% |
| 2019-12-31 | $36.59 Billion | +10.87% |
| 2018-12-31 | $33.00 Billion | -0.94% |
| 2017-12-31 | $33.31 Billion | +34.73% |
| 2016-12-31 | $24.73 Billion | +17.86% |
| 2015-12-31 | $20.98 Billion | +0.28% |
| 2014-12-31 | $20.92 Billion | +18.81% |
| 2013-12-31 | $17.61 Billion | -10.28% |
| 2012-12-31 | $19.62 Billion | -2.48% |
| 2011-12-31 | $20.12 Billion | +8.26% |
| 2010-12-31 | $18.59 Billion | +3.64% |
| 2009-12-31 | $17.94 Billion | -20.21% |
| 2008-12-31 | $22.48 Billion | +68.11% |
| 2007-12-31 | $13.37 Billion | +21.83% |
| 2006-12-31 | $10.97 Billion | -20.41% |
| 2005-12-31 | $13.79 Billion | -1.13% |
| 2004-12-31 | $13.95 Billion | +17.07% |
| 2003-12-31 | $11.91 Billion | +10.63% |
| 2002-12-31 | $10.77 Billion | +15.42% |
| 2001-12-31 | $9.33 Billion | +7.94% |
| 2000-12-31 | $8.64 Billion | +10.65% |
| 1999-12-31 | $7.81 Billion | -4.33% |
| 1998-12-31 | $8.17 Billion | +5.07% |
| 1997-12-31 | $7.77 Billion | -5.30% |
| 1996-12-31 | $8.21 Billion | -8.61% |
| 1995-12-31 | $8.98 Billion | -1.88% |
| 1994-12-31 | $9.15 Billion | +81.05% |
| 1993-12-31 | $5.05 Billion | +33.70% |
| 1992-12-31 | $3.78 Billion | +13.45% |
| 1991-12-31 | $3.33 Billion | -9.33% |
| 1990-12-31 | $3.68 Billion | +75.78% |
| 1989-12-31 | $2.09 Billion | +2.63% |
| 1988-12-31 | $2.04 Billion | -7.91% |
| 1987-12-31 | $2.21 Billion | +19.18% |
| 1986-12-31 | $1.86 Billion | +18.53% |
| 1985-12-31 | $1.57 Billion | -- |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 7… Read more